Abcam founder Jonathan Milner opposes Danaher buyout; First Wave tries to find new life in Sanofi drug

Ab­cam’s founder Jonathan Mil­ner plans to vote against Dana­her’s $5.7 bil­lion ac­qui­si­tion of the com­pa­ny, he an­nounced Thurs­day.

Mil­ner owns 6.14% of Ab­cam. He found­ed the com­pa­ny in 1998 and re­mained its CEO un­til 2014. Mil­ner be­lieves the deal “sub­stan­tial­ly un­der­val­ues Ab­cam,” ac­cord­ing to the press state­ment.

Mil­ner al­so plans to re­quest that the board of di­rec­tors con­vene a gen­er­al meet­ing to dis­cuss re­plac­ing Ab­cam’s board, CEO, CFO and chair­man. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.